SyntekaBio,Inc. Logo

SyntekaBio,Inc.

An AI-driven drug discovery company using supercomputing to accelerate development.

226330 | KO

Overview

Corporate Details

ISIN(s):
KR7226330009
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학17로 18 -, 대전광역시

Description

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-17 00:00
단일판매ㆍ공급계약체결
Korean 9.4 KB
2025-12-16 00:00
투자판단관련주요경영사항 (Ab-ARS™플랫폼으로 발굴한 항암 및 면역질환 항체 후보물질 기술이전)
Korean 11.8 KB
2025-09-19 00:00
주식등의대량보유상황보고서(약식)
Korean 64.1 KB
2025-09-15 00:00
주식등의대량보유상황보고서(일반)
Korean 100.9 KB
2025-09-12 00:00
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 85.9 KB
2025-09-12 00:00
증권발행결과(자율공시)
Korean 5.6 KB
2025-09-12 00:00
단기차입금감소결정(자율공시)
Korean 7.0 KB
2025-09-12 00:00
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean 12.4 KB
2025-09-12 00:00
주요사항보고서(유상증자결정)
Korean 30.4 KB
2025-09-12 00:00
증권신고서(지분증권) (2025.12)
Korean 2.4 MB
2025-09-03 00:00
주요사항보고서(전환사채권발행결정)
Korean 79.9 KB
2025-09-03 00:00
단기차입금증가결정
Korean 9.1 KB
2025-08-26 00:00
주요사항보고서(자기전환사채매도결정)
Korean 29.5 KB
2025-08-14 00:00
반기보고서 (2025.06)
Korean 1.4 MB
2025-08-11 00:00
주식등의대량보유상황보고서(약식)
Korean 97.1 KB

Automate Your Workflow. Get a real-time feed of all SyntekaBio,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SyntekaBio,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SyntekaBio,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.